Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

Accesswire April 28, 2022

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

Accesswire April 22, 2022

CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

Accesswire April 21, 2022

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Accesswire April 11, 2022

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

Accesswire March 30, 2022

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)

Accesswire March 1, 2022

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Accesswire February 10, 2022

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Accesswire January 17, 2022

dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.

Accesswire January 13, 2022

Direxion Launches mRNA ETF (MSGR)

PR Newswire December 9, 2021

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

Accesswire November 19, 2021

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Accesswire November 18, 2021

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

Accesswire October 12, 2021

CureVac Streamlines European Network for mRNA Product Manufacturing

Accesswire September 14, 2021

CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet

Accesswire August 31, 2021

CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

Accesswire August 30, 2021

CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update

Accesswire August 16, 2021

CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60

Accesswire June 30, 2021

CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)

Accesswire June 30, 2021

CureVac Announces Voting Results of General Meeting

Accesswire June 25, 2021